Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213712/edgewise-ewtx-rallies-35-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213712
Jan 22, 2024 - Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
0
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518
Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
0
Here's Why Investors May Bet on BioMarin (BMRN) Stock Now
https://www.zacks.com/stock/news/2215118/here-s-why-investors-may-bet-on-biomarin-bmrn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2215118
Jan 24, 2024 - Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.
0
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2192301
Dec 01, 2023 - Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
0
Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry
https://www.zacks.com/stock/news/2193043/apellis-apls-rides-on-syfovre-to-fuel-growth-amid-rivalry?cid=CS-ZC-FT-analyst_blog|zer_report_update-2193043
Dec 04, 2023 - Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.
0
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193794
Dec 05, 2023 - Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
0
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
https://www.zacks.com/stock/news/2193796/alterity-athe-up-on-preclinical-parkinson-s-treatment-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193796
Dec 05, 2023 - Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
0
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
https://www.zacks.com/stock/news/2194285/pfizer-pfe-arvinas-post-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194285
Dec 06, 2023 - Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
0
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
https://www.zacks.com/stock/news/2195640/merck-s-mrk-keytruda-lynparza-combo-fails-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195640
Dec 08, 2023 - After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
0
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
https://www.zacks.com/stock/news/2207168/ligand-lgnd-up-9-on-fda-nod-for-molluscum-infection-gel?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207168
Jan 08, 2024 - Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.
0
<Page 2